Archive for June, 2013

Drug Patent Expirations for Jun 2 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for June 2 2013

Tradename Applicant Generic Name Patent
Expiration
FOSAMAX

Merck And
Co Inc

alendronate
sodium

Jun 2,
2013
FOSAMAX PLUS
D

Merck

alendronate sodium;
cholecalciferol

Jun 2,
2013
IMITREX

Glaxosmithkline

sumatriptan

Jun 2, 2013

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.

DrugPatentWatch Infographics

Which pharma companies have the most drug patents

Which Companies Have the Most Active Drug
Patents?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Supreme Court Both Invalidates & Upholds Myriad Patents

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. In a 9-0 decision (with brief concurrence by Justice Scalia) in Association for Molecular Pathology v. Myriad (‘Myriad’), argued April 15, 2013 and decided June 13, 2013, the […]


Nasonex bee: Creepy or sexy?

The Nasonex Drug Ad analysis at DrugChatter.com is pretty close to even, with 40/60 split between people not liking and liking the ads. Some people find the bee ‘sexy’ and like its voice, whereas others think the bee is creepy. What’s your opinion? Post your thoughts to twitter and get counted! For more drug sentiment […]


Drug Patent Expirations for May 27 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for May 27 2013

Tradename Applicant Generic Name Patent
Expiration
ADRENACLICK

Amedra
Pharms

epinephrine

May 27, 2013

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.

DrugPatentWatch Infographics

Which pharmaceutical companies listed the most drug patents last<br />
year

Which Companies Listed the Most Drug
Patents Last Year?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Drug Patent Expirations for May 27 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for May 27 2013

Tradename Applicant Generic Name Patent
Expiration
ADRENACLICK

Amedra
Pharms

epinephrine

May 27, 2013

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.

DrugPatentWatch Infographics

Which pharmaceutical companies listed the most drug patents last<br />
year

Which Companies Listed the Most Drug
Patents Last Year?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


The evolving concept of value add in university commercialisation

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
The evolving concept of value add in university commercialisation
Go to paperABSTRACT: Universities have been challenged to assess what value creation mean…


Drug Patent Expirations for May 18 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for May 18 2013

Tradename Applicant Generic Name Patent
Expiration
OSMOPREP

Salix
Pharms

sodium
phosphate, dibasic, anhydrous; sodium phosphate, monobasic,
monohydrate

May 18,
2013
VISICOL

Salix
Pharms

sodium
phosphate, dibasic anhydrous; sodium phosphate, monobasic,
monohydrate

May 18,
2013

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.

DrugPatentWatch Infographics

Which drugs have the most patents

Which
Drugs Have the Most Patents?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Drug Patent Expirations for May 14 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for May 14 2013

Tradename Applicant Generic Name Patent
Expiration
DEPOCYT

Pacira
Pharms Inc

cytarabine

May 14, 2013
ZOMIG

Astrazeneca

zolmitriptan

May 14, 2013
ZOMIG

Ipr

zolmitriptan

May 14, 2013
ZOMIG-ZMT

Astrazeneca

zolmitriptan

May 14, 2013

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.

DrugPatentWatch Infographics

Which drug companies face the most patent expirations

Which Companies Face the Most Patent
Expirations?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Drug Patent Expirations for May 13 2013

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for May 13 2013

Tradename Applicant Generic Name Patent
Expiration
ZAVESCA

Actelion
Pharms Ltd

miglustat

May 13, 2013

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.

DrugPatentWatch Infographics

Which drugs have the most patents

Which
Drugs Have the Most Patents?

More
infographics &raquo





DrugPatentWatch Serves Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.